Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Tongli Pharmaceuticals (USA), Inc.Financial_Report.xls
EX-31.1 - EXHIBIT 31.1 - Tongli Pharmaceuticals (USA), Inc.v323143_ex31-1.htm
EX-32.2 - EXHIBIT 32.2 - Tongli Pharmaceuticals (USA), Inc.v323143_ex32-2.htm
EX-31.2 - EXHIBIT 31.2 - Tongli Pharmaceuticals (USA), Inc.v323143_ex31-2.htm
EX-32.1 - EXHIBIT 32.1 - Tongli Pharmaceuticals (USA), Inc.v323143_ex32-1.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A

Amendment No. 1

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the quarterly period ending June 30, 2012

 

OR

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from ________    to ________.

 

Commission file number: 000-52954

 

Tongli Pharmaceuticals (USA), Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   84-1090791

(State or other jurisdiction

of incorporation or organization)

 

(IRS Employer

Identification number)

     

116 Village Boulevard, Suite #200,

Princeton, NJ, 08540

  10005
(Address of Principal Executive Offices)   (Zip Code)

 

212-842-8837            212-842-8837      

(Registrant’s Telephone Number, Including Area Code)

 

n/a

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x  No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes x  No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company.  See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one): Yes ¨  No  ¨

 

Large accelerated filer ¨   Accelerated filer ¨
Non-accelerated filer ¨   Smaller reporting company x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes ¨ No x

 

As of August 13, 2012, there were 13,548,122 shares of company’s common stock issued and outstanding.

 

 
 

 

Explanatory Note

 

The purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q of Tongli Pharmaceuticals (USA), Inc. for the quarterly period ended June 30, 2012, filed with the Securities and Exchange Commission on August 14, 2012 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).

 

No other changes have been made to the Form 10-Q.  This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

 

Item 6. Exhibits.
   
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the SOX of 2002
   
31.2 Certification of Chief Financial Officer pursuant to Section 302 of the SOX of 2002
   
32.1 Certificate of Chief Executive Officer pursuant to 18 U.S.C.ss.1350
   
32.2 Certificate of Chief Financial Officer pursuant to 18 U.S.C.ss.1350
   
101.INS* XBRL Instance Document
   
101.SCH* XBRL Taxonomy Extension Schema Document
   
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
   
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
   
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
   
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document

 

* XBRL (eXtensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these section.

 

 
 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Tongli Pharmaceuticals (USA), Inc.
     
September 6, 2012 By: /s/ Mingli Yao
 

Mingli Yao

Chief Executive Officer

(Principal Executive Officer)

     
September 6, 2012 By: /s/ Li Li
 

Li Li

Chief Financial Officer

(Principal Accounting Officer)